Search Results - "Mukhametshina, G."

Candidate markers of homologous recombination deficiency for triple negative breast cancer by Havrysh, K.V., Mukhametshina, G., Petrov, S., Safina, S., Kiyamova, R.

Get full text

Potential prognostic markers for recurrence and survival in triple-negative breast cancer by Havrysh, K.V., Mukhametshina, G., Safina, S., Petrov, S., Kiyamova, R.G.

Get full text

Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study by Fedyanin, M., Chubenko, V., Belonogov, A., Beluhin, S., Belyaeva, A., Bolotina, L., Vladimirova, L., Zhabina, A., Zagorskaya, L., Khalikova, L., Fakhrudinova, O., Moiseenko, F., Khasanova, A., Musaeva, H., Novikova, O., Stradaeva, I., Mukhametshina, G., Orlova, R., Micshenko, A., Popova, I., Mukova, L., Kertiev, B.

Get full text

Afatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial by Passaro, A., Laktionov, K.K., Poltoratskiy, A., Egorova, I., Hochmair, M., Migliorino, M.R., Metro, G., Gottfried, M., Tsoi, D., Ostoros, G., Rizzato, S., Mukhametshina, G.Z., Schumacher, M., Novello, S., Dziadziuszko, R., Tang, W., Clementi, L., Cseh, A., Kowalski, D., De Marinis, F.

Get full text

HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin by Rugo, H, Barve, A, Waller, C, Bronchud, M.H, Herson, J, Yuan, J, Manikhas, A, Bondarenko, I, Mukhametshina, G, Nemsadze, G, Parra, J, Abesamis Tiambeng, M.L, Baramidze, K, Akewanlop, C, Vynnychenko, I, Sriuranpong, V, Mamillapalli, G, Ray, S, Yanez Ruiz, E.P, Pennella, E

Get full text

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study by Kovalenko, E. I., Artamonova, E. V., Bolotina, L. V., Zhiliaeva, L. A., Ponomarenko, D. M., Karabina, E. V., Mukhametshina, G. Z., Khasanova, A. I., Ratner, E. Yu, Safarova, A. R., Manikhas, A. G., Popova, N. O., Evstigneeva, I. V., Vladimirova, L. Yu, Kramskaya, L. V., Karandeeva, T. V., Suslova, I. R., Romanchuk, O. V., Shikina, V. E., Povyshev, A. Yu, Osipov, M. A., Cherniakova, E. M., Dergunov, A. S., Volkonskiy, M. V., Chernov, I. S., Shumskaya, I. E., Fael, M. M., Garifullina, V. I., Gudkova, I. E.

“…Introduction . The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd…”
Get full text

392PCandidate markers of homologous recombination deficiency for triple negative breast cancer by Havrysh, K V, Mukhametshina, G, Petrov, S, Safina, S, Kiyamova, R

Get full text

46PPotential prognostic markers for recurrence and survival in triple-negative breast cancer by Havrysh, K V, Mukhametshina, G, Safina, S, Petrov, S, Kiyamova, R G

Get full text

296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA by Wu, Y-L., Tsuboi, M., Grohe, C., John, T., Majem Tarruella, M., Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vinh Vu, H., Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A., Huang, X., Herbst, R.S.

Get full text

Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC by Shustova, M., Burdaeva, O., Alexeev, S., Shelepen, K., Khorinko, A., Mukhametshina, G., Sheveleva, L., Ivanov, R.

Get full text

LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA by Tsuboi, M., Wu, Y-L., Grohe, C., John, T., Tarruella, M. Majem, Wang, J., Kato, T., Goldman, J.W., Kim, S-W., Yu, C-J., Vu, H. Vinh, Mukhametshina, G., Akewanlop, C., de Marinis, F., Shepherd, F.A., Urban, D., Stachowiak, M., Bolanos, A.L., Huang, X., Herbst, R.S.

Get full text

Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience by Kovalenko, E., Manzyuk, L., Gorbunova, V., Kolyadina, I., Bolotina, L., Zhilyaeva, L., Ponomarenko, D., Karabina, E., Mukhametshina, G., Khasanova, A., Ekaterina, R., Safarova, A., Manikhas, A., Volkonsky, M., Kramskaya, L., Karandeeva, T., Suslova, I., Popova, N., Evstigneeva, I., Shumskaya, I.

Get full text

P137 - Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: real life experience by Manikhas, A., Gorbunova, V., Manzyuk, L., Kovalenko, E., Bolotina, L., Zhukova, L., Vladimirova, L., Kolyadina, I., Ponomarenko, D., Mukhametshina, G.

Get full text

Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: real life experience by Manikhas, A., Gorbunova, V., Manzyuk, L., Kovalenko, E., Bolotina, L., Zhukova, L., Vladimirova, L., Kolyadina, I., Ponomarenko, D., Mukhametshina, G.

Get full text

P-291 Retrospective comparison efficacy and toxicity FOLFIRI plus aflibercept or bevacizumab in patients with metastatic colorectal cancer: Results of the multicenter observational study by Fedyanin, M., Chubenko, V., Belonogov, A., Beluhin, S., Vladimirova, L., Zhabina, A., Kudryavtseva, A., Moiseenko, F., Khasanova, A., Musaeva, H., Novikova, O., Stradaeva, I., Mukhametshina, G., Orlova, R., Micshenko, A., Popova, I., Lyadova, M., Popova, A., Bolotina, L., Kertiev, B., Kuzmina, E., Tjulandin, S.

Get full text

1472PAfatinib in EGFR TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study by de Marinis, F, Laktionov, K K, Poltoratskiy, A, Egorova, I, Hochmair, M, Passaro, A, Migliorino, M R, Metro, G, Gottfried, M, Tsoi, D, Ostoros, G, Rizzato, S, Mukhametshina, G Z, Schumacher, M, Novello, S, Tang, W, Clementi, L, Cseh, A, Kowalski, D M

“…Abstract Background First-line afatinib demonstrated significantly improved PFS in patients with EGFRm+ NSCLC vs chemotherapy in LUX-Lung 3/6 (HR, 95% CI:…”
Get full text

P-130Factors associated with the efficacy of aflibercept in patients with metastatic colorectal cancer: results of the multicenter observational study by Fedyanin, M, Chubenko, V, Belonogov, A, Beluhin, S, Belyaeva, A, Bolotina, L, Vladimirova, L, Zhabina, A, Zagorskaya, L, Khalikova, L, Fakhrudinova, O, Moiseenko, F, Khasanova, A, Musaeva, H, Novikova, O, Stradaeva, I, Mukhametshina, G, Orlova, R, Micshenko, A, Popova, I, Mukova, L, Kertiev, B

Get full text

115OAfatinib in EGFR TKI-naïve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial by Passaro, A, Laktionov, K K, Poltoratskiy, A, Egorova, I, Hochmair, M, Migliorino, M R, Metro, G, Gottfried, M, Tsoi, D, Ostoros, G, Rizzato, S, Mukhametshina, G Z, Schumacher, M, Novello, S, Dziadziuszko, R, Tang, W, Clementi, L, Cseh, A, Kowalski, D, De Marinis, F

Get full text

Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study by M.   Yu. Fedyanin, L.  Yu.  Vladimirova, V.  A.  Chubenko, L.   A. Zagorskaya, A.  V.  Belyaeva, O.  L.  Fakhrutdinova, S.  A.  Belukhin, A.   S. Zhabina, L.   V. Khalikova, L.  V.  Bolotina, R.   V. Orlova, F.  V.  Moiseenko, G.   Z. Mukhametshina, A.  I.  Khasanova, A.  V.  Belonogov, Kh.  S.  Musaeva, O.  Yu.  Novikova, I.  Yu.  Stradaeva, I.  L.  Popova, S.  P.  Erdniev, A.  K.  Ivanova, A.  V.  Androsova, P.  S.  Feoktistova, E.  S.  Kuzmina, E.   V. Karabina, O.  V.  Nekrasova, O.  V.  Sekhina, A.   A. Mishchenko, L.  A.  Mukova, B.  Kh.  Kertiev, G.  I.  Kosar, S.   N. Osodoeva, A.  I.  Kats, R.  R.  Malina, M.  A.  Lyadova, A.  A.  Tryakin, S.  A.  Tyulandin

“…Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic…”
Get full text

Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab by Rugo, H., Barve, A., Waller, C.F., Bronchud, M., Herson, J., Yuan, J., Manikhas, A., Bondarenko, I., Mukhametshina, G., Nemsadze, G., Parra, J.D., Abesamis-Tiambeng, M.L.T., Baramidze, K., Akewanlop, C., Vynnychenko, I., Sriuranpong, V., Mamillapalli, G., Ray, S., Ruiz, E.P. Yanez, Pennella, E.

Get full text